Hims & Hers Stock Plunges 27%

This is a news story, published by Yahoo Finance, that relates primarily to Hims & Hers news.

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

weight loss

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest loss prescription Zepbound news, loss drugs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

FDA

Yahoo Finance

•

Health

Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs

Summary

Nutrition label

79% Informative

Hims & Hers (HIMS) stock plunged 27% on Tuesday after the company announced it would soon stop offering some compounded versions of weight-loss drugs.

The company's fourth quarter results came in better than expected, but investors were spooked over the potential loss in revenue from the GLP-1 segment.

Despite the recent tumble, shares are still up 48% year to date .

On Tuesday , Novo Nordisk's Ozempic and Wegovy stock rose 2% .

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive